Subodh Bhuchar, MD
Family Medicine · Sugar Land, TXNPI 1629082417
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 461 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$891
- Lilly USA, LLC$715
- Boehringer Ingelheim$694
- Bayer$601
- GSK$477
- plus $4K from 33 others
Across 243 payments — averaging $4976.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$291K
- Ardelyx, Inc.$261K
- AstraZeneca$143K
- GSK$138K
- Amgen$110K
- AbbVie$100K
- plus $166K from 5 others
What the payments were for
- Food & beverage$8,296100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 74 | $1,236 |
| AstraZeneca | 51 | $891 |
| Lilly USA, LLC | 43 | $715 |
| Boehringer Ingelheim | 34 | $694 |
| Bayer | 30 | $601 |
| GSK | 24 | $477 |
| Amgen | 24 | $457 |
| Merck | 32 | $423 |
| Amarin Pharma, Inc. | 25 | $345 |
| AbbVie(2 entities) | 15 | $312 |
| Sanofi-aventis U.S. LLC | 14 | $252 |
| Pfizer | 10 | $196 |
| Biohaven Pharmaceuticals, Inc. | 3 | $151 |
| Optinose US, Inc. | 7 | $145 |
| Dexcom, Inc. | 6 | $135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $128 |
| Renalytix AI, Inc. | 6 | $123 |
| Johnson & Johnson | 7 | $115 |
| Cranial Technologies, Inc | 8 | $111 |
| Corcept Therapeutics | 4 | $101 |
| Exact Sciences | 5 | $94 |
| Novartis | 4 | $93 |
| Astellas Pharma US Inc | 4 | $77 |
| Sanofi Pasteur Inc. | 3 | $65 |
| Intuity Medical Inc | 3 | $57 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $51 |
| Genentech USA, Inc. | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $35 |
| Redhill Biopharma Inc. | 2 | $29 |
| Mylan Specialty L.p. | 1 | $21 |
| Abbott | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Seqirus USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$123
How this compares
$8,309 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $144,122 |
| JardianceEmpagliflozin | 69 | $99,430 |
| JanuviaSitagliptin Phosphate | 36 | $52,204 |
| MounjaroTirzepatide | 34 | $50,771 |
| FarxigaDapagliflozin Propanediol | 28 | $34,487 |
| TrulicityDulaglutide | 22 | $26,908 |
| EliquisApixaban | 20 | $26,468 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $24,196 |
| VascepaIcosapent Ethyl | 29 | $21,263 |
| ProliaDenosumab | 12 | $20,398 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $14,484 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 37 | $11,560 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $6,824 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $5,135 |
| Colesevelam Hcl | 13 | $4,780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,236 | $144,12280 claims |
| Boehringer IngelheimJardiance | $694 | $99,43069 claims |
| Lilly USA, LLCMounjaro, Trulicity | $715 | $77,67956 claims |
| MerckJanuvia, Janumet | $423 | $66,68747 claims |
| GSKTrelegy Ellipta, Arexvy | $477 | $35,75663 claims |
| AstraZenecaFarxiga | $891 | $34,48728 claims |
| PfizerEliquis | $196 | $26,46820 claims |
| AmgenProlia | $457 | $20,39812 claims |
| AbbVieSynthroid | $312 | $1,26214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Sugar Land
- Anne Marie Ponce de LeonSugar Land$109K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.